APA (7th ed.) Citation

Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., . . . Budde, L. E. (2025). Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood, 145(7), . https://doi.org/10.1182/blood.2024025454

Chicago Style (17th ed.) Citation

Sehn, Laurie H., et al. "Long-term 3-year Follow-up of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma After ≥2 Prior Therapies." Blood 145, no. 7 (2025). https://doi.org/10.1182/blood.2024025454.

MLA (9th ed.) Citation

Sehn, Laurie H., et al. "Long-term 3-year Follow-up of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma After ≥2 Prior Therapies." Blood, vol. 145, no. 7, 2025, https://doi.org/10.1182/blood.2024025454.